ALK and neuroblastoma: Nevertheless, genes infrequently mutated but acting in molecular mechanisms underlying the oncogenesis and progression of neuroblastoma remain unknown, and targeted therapies identified to date, such as ALK inhibitors, might benefit a reduced number of patients [14].